{"filings":[{"id":945404,"accession_number":"0001193125-26-263722","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2026-06-09T20:05:20+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve Amended and Restated 2018 Equity Incentive Plan adding 1.76M new shares plus annual increases","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan approved with 11.14M for, 433K against; adds 1,756,257 new shares to reserve plus annual 5% increases from 2027-2036.","Directors Paul B. Manning and Lawrence Eichenfield re-elected with 11.54M and 11.52M votes for, respectively.","Advisory vote on executive compensation passed with 11.56M for, 34K against.","Ratification of KPMG LLP as independent auditor for fiscal year 2026 approved with 14.06M for.","Plan effective immediately upon stockholder approval on June 5, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40283,"accession_number":"0001193125-26-219395","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2026-05-12T20:07:19+00:00","items":["2.02","9.01"],"status":"ready","headline":"Verrica Q1 2026: Net revenue $5.0M; YCANTH units up 51% YoY; net loss $9.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["YCANTH dispensed units 15,302 (+12.1% QoQ, +51.3% YoY); net product revenue $4.3M (+16.2% QoQ, +25.4% YoY).","Total revenue $5.0M includes $0.7M license/collaboration revenue from Torii Japan launch.","Net loss $9.7M ($0.45 per share); non-GAAP net loss $8.8M ($0.41 per share).","Phase 3 common warts trial (COVE-2) >50% enrolled; second trial (COVE-3) expected mid-2026.","Appointed Chris Chapman as Chief Commercial Officer; Phase 2 VP-315 BCC data to be presented at SID May 13-16."],"consensus_eps_estimate":-0.3871,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":5023000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106921,"accession_number":"0001193125-26-101126","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Verrica Q4 2025: YCANTH net revenue up 130% to $15.3M; total revenue $35.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product revenue $3.7M vs $0.3M YoY; total revenue $35.6M in 2025, up from $7.6M in 2024.","YCANTH dispensed units up 99% to 51,296 in 2025; SG&A cut by over 40% to $35.2M.","Net loss $17.9M ($1.68/share) for full year 2025 vs $76.6M ($14.78/share) in 2024.","Company has no outstanding debt; cash runway extended into Q1 2027.","Phase 3 for common warts initiated; VP-315 advancing to Phase 3 for basal cell carcinoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123243,"accession_number":"0001193125-25-335824","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Verrica appoints Charles Frantzreb to board, grants performance-based options to CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Charles Frantzreb, Partner at Caligan, appointed to board effective Dec 26, 2025; Class III director term to 2027 annual meeting.","CEO Jayson Rieger granted options for 512,269 shares at $8.21, vesting on stockholder plan amendment and stock price milestones of $15 and $25.","Interim CFO John Kirby granted 10,000 fully vested RSUs on Dec 23, 2025.","Frantzreb designated by Caligan under Securities Purchase Agreement dated Nov 23, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123242,"accession_number":"0001193125-25-292155","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Verrica raises ~$50M in PIPE to retire OrbiMed debt, extend runway into mid-2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$50M from sale of 6.5M shares, 5.3M pre-funded warrants, and 2.95M Series C warrants.","$35M of net proceeds to fully repay OrbiMed credit facility ($50M drawn); remaining for working capital.","Cash runway extended into mid-2027; Q3 2025 cash balance was $21.1M.","Caligan Partners anchors financing, gets right to designate a Class I board member post-closing.","Series C warrants exercisable at $6.315/share, expire 5 years from close; pre-funded at $0.0001/share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123241,"accession_number":"0001193125-25-283078","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Verrica Q3 revenue $14.3M (YCANTH $3.6M, license $10.7M); net loss narrows to $0.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $0.3M ($0.03/sh) vs $22.9M loss ($4.88/sh) in Q3'24; non-GAAP net income $1.2M.","YCANTH dispensed units 14,093 in Q3 (+4.9% sequentially); nine-month total 37,642 (+120% YoY).","Received $10M milestone from Torii for Japan YCANTH approval; global Phase 3 for common warts started.","FDA aligned on Phase 3 design for VP-315 in basal cell carcinoma; positive EMA feedback supports MAA filing.","Cash $21.1M; sales force expanded to 45 reps, targeting 50 in 2026."],"consensus_eps_estimate":-0.6885,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":30485000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139923,"accession_number":"0001193125-25-178954","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Verrica Q2 net income $0.2M; YCANTH units +32.8% QoQ; Nasdaq compliance regained","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 product revenue $4.5M; license & collaboration revenue $8.2M (incl. $8.0M Torii milestone). Net income $0.2M ($0.02 GAAP EPS) vs net loss $17.2M YoY.","YCANTH dispensed applicator units 13,434, sequential growth of 32.8% over Q1'25. Revenue net $4.5M up 32.5% sequentially.","Regained Nasdaq bid price compliance after 1-for-10 reverse stock split on July 24, 2025.","Torii accelerated $8M milestone payment received July 2025; additional $10M milestone upon Japanese YCANTH approval expected by end of 2025.","Completed End-of-Phase 2 meeting with FDA for VP-315 (basal cell carcinoma); preparing Phase 3 program and exploring non-dilutive funding."],"consensus_eps_estimate":-0.7191,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":16141000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139922,"accession_number":"0001193125-25-169309","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Verrica receives Nasdaq delisting notice, implements 1-for-10 reverse split to regain bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Staff Determination issued July 24, 2025; company may request hearing to stay delisting.","1-for-10 reverse stock split effected July 24, 2025 to increase per-share bid price.","Closing bid price $6.24 on July 29, 2025, above $1.00 minimum for 4 consecutive business days.","Company will request bid price compliance determination after 10 trading days of compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139921,"accession_number":"0001193125-25-162939","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["3.03","9.01"],"status":"ready","headline":"Verrica Pharmaceuticals Announces 1-for-10 Reverse Stock Split Effective July 24, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Verrica Pharmaceuticals (VRCA) filed a Certificate of Amendment to effect a 1-for-10 reverse stock split, authorized by stockholders on June 5, 2025.","The reverse stock split becomes effective at 5:00 p.m. ET on July 24, 2025; trading on Nasdaq on a split-adjusted basis begins July 25, 2025.","Outstanding shares will be reduced from approximately 92.5 million to about 9.25 million, with no fractional shares issued; cash paid in lieu.","Proportionate adjustments will be made to exercise price and number of shares issuable under stock options, warrants, and equity plans.","The new CUSIP number for VRCA common stock post-split is 92511W207."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139920,"accession_number":"0001193125-25-153471","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Verrica amends Torii deal: $8M milestone accelerated, $10M on Japan approval, $40M trial funding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Torii pays $8M milestone in July 2025 for starting global Phase 3 common warts trial of YCANTH.","Torii to pay $10M cash upon Japanese approval of YCANTH for molluscum, expected by end-2025.","Torii funds first $40M of trial costs (~90% of budget); Verrica repays via future royalties/transfer price.","First patient dosing in U.S. Phase 3 common warts trial expected Q4 2025.","OrbiMed waived going-concern qualification requirement under credit agreement for remainder of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157523,"accession_number":"0001193125-25-139959","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Verrica amends credit agreement, waives going concern covenant through Dec 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Sixth amendment waives Section 7.1(b) and 7.1(c) going concern qualifications for Q2'25, Q3'25, and FY2025 financial statements.","Company paid amendment fee of $110,465.12 to lenders (OrbiMed Royalty & Credit Opportunities IV, LP).","Original credit agreement dated July 26, 2023; all other terms unchanged.","Waiver addresses potential default risk from going concern audit language in upcoming filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157522,"accession_number":"0001193125-25-135949","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Verrica stockholders elect three directors, approve reverse split authorization at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected directors Sean Stalfort (60.3M for), Diem Nguyen (58.8M for), Gavin Corcoran (63.0M for).","Advisory vote on named executive officer compensation approved: 62.4M for, 1.3M against.","Ratification of KPMG LLP as auditor for FY2025 approved: 81.9M for, 1.5M against.","Approved reverse stock split authorization at ratio of 1-for-10 to 1-for-30, board discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157521,"accession_number":"0001193125-25-118839","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Verrica Q1 2025: YCANTH revenue $3.4M; dispensed 10,102 units (+16.7% QoQ)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.7M ($0.10/share) vs. $20.3M ($0.44) in Q1 2024; non-GAAP net loss $7.8M.","YCANTH revenue $3.4M from >10K applicator units dispensed, a company record and 16.7% sequential growth.","Cash and equivalents $29.6M as of March 31, 2025.","Appointed Noah Rosenberg as CMO (March) and Gavin Corcoran to Board (April).","Completed end-of-Phase 2 meeting with FDA for VP-315 (basal cell carcinoma); global Phase 3 for common warts advancing with Torii."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":3439000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157520,"accession_number":"0001193125-25-096909","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Verrica Pharmaceuticals' Chief Legal Officer Christopher Hayes resigns effective April 30, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher G. Hayes resigns as Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary effective April 30, 2025.","Company enters Release Agreement providing 12 months of base salary continuation and up to 12 months of COBRA coverage.","No permanent replacement has been announced for Hayes' roles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157519,"accession_number":"0001193125-25-071389","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Verrica appoints Gavin Corcoran to board as Class I director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Corcoran appointed effective March 31, 2025; term expires at 2025 annual meeting.","Granted option to purchase 17,502 shares at grant-date closing price; vests over 3 years.","Receives $40,000 annual retainer; eligible for annual option of 20,000 shares.","Currently Chief Development Officer of Formation Bio; former CMO of Allergan and Actavis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175898,"accession_number":"0001193125-25-051957","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Verrica Q4 product revenue $0.3M, net loss $0.24/sh; YCANTH units up 12.3% sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product revenue $0.3M (vs $1.9M in 2023); FY product revenue $6.6M (vs $4.7M) with $3.2M returns reserve.","Q4 GAAP net loss $16.2M ($0.24/sh) vs $24.6M ($0.53/sh); FY loss $76.6M ($1.48/sh) vs $67.0M ($1.48/sh).","YCANTH dispensed units 8,654 in Q4 (+12.3% QoQ); operating expenses cut ~50% after restructuring with $1.0M charge.","Cash $46.3M at Dec 31; $8M Torii milestone upon Phase 3 common warts start and $25M Series A warrants could extend runway; GAAP raises going concern doubt.","VP-315 Phase 2 shows 97% ORR and ~51% complete histological clearance; Phase 3 for common warts could begin mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175897,"accession_number":"0001193125-25-032003","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Verrica enters lender waiver of going concern covenants for FY2024, Q1 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lenders waive covenant requiring no going concern qualification in Dec 2024 and Mar 2025 financials.","Waiver is with OrbiMed Royalty & Credit Opportunities IV, LP under Credit Agreement dated July 2023.","Remaining terms of Credit Agreement unchanged; waiver filed with 10-K.","This indicates auditor likely issued going concern opinion, signaling potential financial distress."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175896,"accession_number":"0001193125-25-017264","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Verrica receives Nasdaq deficiency notice; stock below $1 for 30 days, 180-day cure period until July 23, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Verrica on Jan 24, 2025 that bid price closed below $1.00 for 30 consecutive days, violating Listing Rule 5450(a)(1).","Company has 180 days (until July 23, 2025) to regain compliance by closing at $1.00+ for 10 consecutive business days.","If not cured, Verrica may transfer to Nasdaq Capital Market by paying $5,000 fee and meeting other standards except bid price.","Company is considering options including reverse stock split and application to transfer to Nasdaq Capital Market.","No immediate impact on listing; delisting risk if compliance not achieved within cure periods."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192801,"accession_number":"0001193125-24-273406","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Verrica appoints David Zawitz as COO effective Dec 9; grants 950,000 option shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Zawitz appointed Chief Operating Officer and principal operating officer, effective Dec 9, 2024.","Base salary of $250,000/year; target annual bonus of 40% of base salary.","Option grant for 950,000 shares at closing price on grant date, vesting over 4 years with accelerated vesting on change-in-control termination.","2024 Inducement Plan shares increased from 2,000,000 to 4,500,000 to accommodate the grant.","Zawitz to continue consulting for PBM Capital with Board approval for increased time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192800,"accession_number":"0001193125-24-263477","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Verrica prices $42M public offering of common stock and warrants at $0.89/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$42M gross from 44.96M common shares, 2.24M pre-funded warrants, and 47.2M Series A/B warrants at $0.89/unit.","Series A warrants exercisable at $1.068/sh, expire 1 year; Series B at $1.335/sh, expire 5 years.","Offering expected to close Nov 22, 2024; Jefferies sole bookrunner with 30-day option for up to 7.08M additional shares.","Pre-funded warrants have $0.0001 exercise price and 9.99% beneficial ownership limitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192799,"accession_number":"0001193125-24-262615","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Verrica launches underwritten public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of common stock (or pre-funded warrants) and accompanying warrants; Jefferies sole bookrunner; 30-day option for 15% additional.","Terminated ATM equity prospectus; no shares had been issued under the Open Market Sales Agreement with Jefferies.","Targeting monthly operating cash flow break-even in H2 2025 after restructuring sales force from 80 to ~33 territories.","Phase 2 data for VP-315 in BCC: 86% tumor size reduction, 51% complete histological clearance (n=90); End-of-Phase 2 meeting planned H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192798,"accession_number":"0001193125-24-250638","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Verrica Q3 net product revenue negative $1.9M; CEO Ted White resigns, replaced by Dr. Rieger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Negative net product revenue of $1.9M in Q3 2024, including $1.7M provision for returns; no ex-factory sales.","Net loss of $22.9M ($0.49 per share) vs $24.8M ($0.54) in Q3 2023; non-GAAP loss $20.2M.","CEO Ted White resigns effective Nov 5; Dr. Jayson Rieger appointed President, CEO, and director.","John Kirby appointed Interim CFO; company engaged Jefferies to advise on strengthening balance sheet.","Restructuring cuts operating expenses ~50%; VP-315 Phase 2 shows 51% complete histologic clearance for BCC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192797,"accession_number":"0001193125-24-234391","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["5.02","3.01"],"status":"ready","headline":"Verrica out of Nasdaq compliance after director resignation; cure period granted","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Craig Ballaron resigned from Board effective October 2, 2024.","Board appointed Diem Nguyen to Audit Committee on October 7, 2024.","Resignation caused loss of majority independent directors, violating Nasdaq Rule 5605(b)(1).","Nasdaq provided cure period until next annual meeting or October 2, 2025.","Company expects to regain compliance within the cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192796,"accession_number":"0001193125-24-230240","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Verrica cuts 47 jobs, expects $1.0M restructuring charge","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of 47 employees, substantially completed by October 1, 2024.","Total restructuring expense estimated at $1.0M: $0.7M termination costs and $0.3M vehicle sale loss.","Charge to be recorded in Q4 2024; cash payments expected by November 30, 2024.","Board approved September 23, 2024 to streamline operations and preserve capital.","One-time costs are the only direct expenses of the restructuring plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209233,"accession_number":"0001193125-24-227975","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Verrica CFO Terence Kohler resigns effective Oct 4, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Terence Kohler notified company of resignation on Sep 23, 2024.","Resignation effective October 4, 2024; Kohler leaving to pursue new business opportunity.","No successor or interim CFO named; CEO Ted White signs the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209232,"accession_number":"0001193125-24-215180","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Verrica confirms separation agreements with former CCO Joe Bonaccorso","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["On August 30, 2024, Verrica entered into Release and Consulting Agreements with former CCO Joe Bonaccorso.","Terms of the agreements were disclosed on August 27, 2024 and remain unchanged.","The agreements formalize Bonaccorso's departure as Chief Commercial Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209231,"accession_number":"0001193125-24-207814","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2024-08-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Verrica CCO Joe Bonaccorso resigns effective Aug 30, 2024; consulting role through Aug 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joe Bonaccorso resigns as Chief Commercial Officer effective August 30, 2024.","Separation benefits include 12 months base salary and up to 12 months COBRA coverage.","Consulting Agreement runs through August 30, 2025, with no cash compensation; outstanding equity continues vesting.","Company expects to enter into Release and Consulting Agreements with Bonaccorso."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209230,"accession_number":"0001193125-24-200247","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Verrica Q2 2024: YCANTH revenue $4.9M; net loss $17.2M; positive Phase 2 BCC data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue of $4.9M from YCANTH; net loss $17.2M ($0.37/sh) vs $11.0M ($0.24/sh) in Q2 2023.","Cash and equivalents $31.9M; expects runway into Q1 2025.","Phase 2 VP-315: 51% complete histologic clearance of basal cell carcinoma; no serious adverse events.","Permanent J-Code for YCANTH effective Apr 1; settlement with Dormer Labs to stop unapproved cantharidin sales in US.","Amended Torii agreement: equal cost split for Phase 3 common warts trial; $8M milestone at first Japan patient dosed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":9003000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209229,"accession_number":"0001193125-24-193923","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Verrica amends credit deal with OrbiMed; revenue test delayed, exit fee hiked, going concern waived","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revenue test under Credit Agreement now begins December 31, 2024, instead of earlier date.","Lenders waived going concern qualification requirement for Q2 and Q3 2024 financial statements.","Exit Fee on Initial Loans increased from 5.00% to 7.50%.","YCANTH net revenue must meet specified thresholds to avoid principal payments under amended terms.","Fifth Amendment modifies July 2023 Credit Agreement; other terms unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227166,"accession_number":"0001193125-24-172277","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Verrica amends credit agreement with OrbiMed; revenue test deferred to Sept 30, 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment to Credit Agreement moves revenue test start from earlier date to September 30, 2024.","$500,000 amendment fee paid to lenders in connection with the amendment.","Revenue test determines if principal payments (including premium) are required based on YCANTH net revenue.","No other terms of the Credit Agreement were changed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227165,"accession_number":"0001193125-24-158353","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders elect directors and approve advisory proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Ted White (13,091,028 for) and Mark Prygocki (12,503,147 for) as directors.","Advisory vote on executive compensation approved: 12,760,245 for, 1,932,076 against.","Advisory vote on frequency of say-on-pay: one year selected with 14,797,140 votes.","Ratification of KPMG LLP as independent auditor approved: 37,151,871 for, 678,830 against.","Approximately 89.2% of outstanding shares were present or represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227164,"accession_number":"0001193125-24-138898","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Verrica amends Torii deal: jointly fund Phase 3 common-warts trial; gets $8M milestone, issues warrant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment equally splits cost of global Phase 3 trial of YCANTH for common warts; Torii funds upfront, Verrica repays half with interest (SOFR+2% min 6%).","Torii to pay $8M milestone upon first patient dosed in Japan; trial expected to start H1 2025.","Verrica issues warrant for 500,000 shares at $9.56, vesting on trial milestones (first dose, database lock, NDA submission).","Common warts affects ~22M patients in U.S. with no FDA-approved therapies; Verrica sees multi-billion opportunity.","Torii may invoice Verrica if not repaid within 60 months; termination tied to trial progress."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227163,"accession_number":"0001193125-24-136715","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Verrica Q1 2024: YCANTH revenue $3.2M, net loss $20.3M, cash runway into Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["YCANTH product revenue of $3.2M; no prior-year comparable as sales began Q3 2023.","Net loss $20.3M ($0.44/sh) vs $6.6M loss ($0.15/sh) in Q1 2023; non-GAAP loss $17.8M.","SG&A expense surged to $16.3M from $4.3M due to commercial ramp; R&D $4.9M vs $2.7M.","Cash and equivalents $48.9M; company expects to fund operations into Q1 2025.","Received NCE status (5-year exclusivity) and permanent J-Code for YCANTH; Phase 2 data for VP-315 (BCC) expected Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":3826000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246052,"accession_number":"0001193125-24-051876","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Verrica Q4 2023 YCANTH revenue $1.9M; net loss $24.6M vs $5.9M prior year","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2023 YCANTH product revenue $4.7M; first commercial revenue after Q3 2023 launch.","Net loss FY 2023 $67.0M ($1.48 per share) vs $24.5M ($0.72 per share) in FY 2022; non-GAAP net loss $51.8M ($1.14 per share).","SG&A expenses surged to $47.3M for FY 2023 (FY 2022: $17.4M) driven by commercial ramp and stock compensation.","Cash and equivalents $69.5M as of Dec 31, 2023; runway into Q2 2025.","CMS issued permanent J-code for YCANTH (effective Apr 1, 2024); FDA aligned on Phase 3 design for common warts; VP-315 Phase 2 top-line data expected H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":5124000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246051,"accession_number":"0001193125-24-003926","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Verrica updates company overview presentation; no material new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing notes company presentation updated on website as of January 8, 2024.","No specific financial, clinical, or operational metrics are provided in the exhibit.","Presentation title slide only; substantive content not included in this filing.","Furnished under Regulation FD, not incorporated by reference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263511,"accession_number":"0001193125-23-274069","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Verrica posts Q3 2023 net loss of $24.8M; first YCANTH revenue $2.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["First commercial YCANTH sale to distributor FFF generated $2.8M product revenue; net loss $24.8M ($0.54/share).","Non-GAAP net loss $14.8M ($0.32/share) vs. non-GAAP net income $2.9M in Q3 2022.","SG&A surged to $20.1M (from $3.9M) due to YCANTH commercial ramp and $7.4M stock compensation.","Over 112M lives covered by commercial/managed Medicaid; fee-for-service Medicaid in 4 states.","Cash $84.3M; closed $125M OrbiMed debt facility ($50M drawn) to fund operations into Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":3136000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280728,"accession_number":"0001193125-23-205590","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Verrica FDA approval of YCANTH for molluscum and Q2 net loss $11M; cash runway to Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA approved YCANTH (cantharidin) on July 21 for molluscum in patients 2+; launch by Sep 2023.","Closed $125M debt facility with OrbiMed; drew $50M, up to $75M additional; cash extends into Q1 2025.","Q2 GAAP net loss $11.0M ($0.24/share) vs $10.2M loss in prior year; non-GAAP loss $9.4M.","Expanding Part 2 enrollment of VP-315 Phase 2 trial for basal cell carcinoma to accelerate development.","Cash and equivalents $55.1M at June 30, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":219000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280727,"accession_number":"0001193125-23-196112","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2023-07-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Verrica posts updated corporate presentation; no specific material changes disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company filed an updated corporate presentation on its website on July 27, 2023.","Presentation content was not fully provided in the filing; only a title page was available.","No financial results, guidance, or strategic updates were detailed in the 8-K or exhibit.","This is a routine Regulation FD disclosure with no new quantitative data for investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280726,"accession_number":"0001193125-23-194625","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Verrica closes $125M debt financing from OrbiMed; $50M funded, $75M tranched on revenue milestones","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$50M borrowed at closing; up to $75M additional available in five tranches subject to YCANTH revenue thresholds.","Five-year term loan matures July 2028; interest rate is one-month SOFR plus 8% (floor 4%).","OrbiMed receives warrant for 518,551 shares at $6.0264 per share (10-year term).","Proceeds support commercialization of YCANTH, FDA-approved July 21, 2023 for molluscum contagiosum.","Cash runway extended into Q1 2025; company believes no additional equity financing needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280725,"accession_number":"0001193125-23-191859","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2023-07-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Verrica FDA approves YCANTH for molluscum; secures up to $125M debt financing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["YCANTH (cantharidin 0.7%) topical solution approved for molluscum contagiosum in patients 2+ years; first FDA-approved treatment for the indication.","Phase 3 CAMP-1: 46% complete clearance vs 18% placebo (p<0.0001); CAMP-2: 54% vs 13% (p<0.0001).","Non-binding term sheet for up to $125M debt facility; $50M available immediately at close, expected by end of week.","Debt is 5-year term loan bearing SOFR + 8% (4% floor); warrant for $3.1M common stock at 10-day VWAP.","Verrica plans commercial launch by September 2023; cash runway extended into Q1 2025 with $60M on hand plus $50M upfront."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299347,"accession_number":"0001193125-23-163516","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Verrica shareholders re-elect three directors; ratify KPMG as auditor for FY2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three director nominees elected: Ballaron (16,697,734 for), Manning (16,965,570), Eichenfield (16,400,406); 17,862,320 broker non-votes.","Ratification of KPMG LLP as independent auditor for FY2023: 34,915,802 for, 1,088 against, 13,730 abstain.","83.46% of 41,852,053 outstanding shares were present or represented at the June 8, 2023 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299346,"accession_number":"0001193125-23-138946","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Verrica Q1 net loss narrows to $6.6M; raised $32.5M; YCANTH PDUFA July 23, 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.6M ($0.15 GAAP EPS) vs $8.5M ($0.31) in Q1 2022; non-GAAP net loss $5.5M ($0.13).","Cash and equivalents $60.0M as of March 31, 2023; management expects runway into Q1 2024.","PDUFA goal date of July 23, 2023 for YCANTH (VP-102) for molluscum contagiosum; no FDA-approved therapy exists.","Raised $32.5M gross proceeds in February 2023 underwritten offering to support pre-commercial activities and VP-315 trial.","VP-315 advanced into Part 2 of Phase 2 study for basal cell carcinoma; Part 3 expected to start first half 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":37000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319506,"accession_number":"0001193125-23-060702","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Verrica reports FY 2022 net loss $24.5M; VP-102 PDUFA set for July 23, 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.5M ($0.72/share) for FY 2022 vs $35.1M ($1.30/share) in FY 2021.","Collaboration revenue of $9.0M in FY 2022, down from $12.0M in FY 2021.","Cash and equivalents $34.3M at Dec 31, 2022; raised $32.5M gross in Feb 2023 secondary offering.","FDA assigned PDUFA date of July 23, 2023 for VP-102 NDA for molluscum contagiosum.","VP-315 Phase 2 Part 2 dosing expected to begin in Q2 2023 for basal cell carcinoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319505,"accession_number":"0001193125-23-043040","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Verrica prices $32.5M underwritten offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["750,000 shares at $6.75 and 4,064,814 pre-funded warrants at $6.7499 per share.","Gross proceeds expected ~$32.5M before underwriting discounts and expenses.","Jefferies LLC acting as sole book-runner; closing expected Feb 23, 2023.","Offering substantially led by one healthcare dedicated fund.","Shelf registration statement (333-268229) effective Dec 19, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319504,"accession_number":"0001193125-23-042756","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Verrica reports $34.3M cash; updates on VP-102 NDA and VP-315 Phase 2 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash and cash equivalents of $34.3M as of Dec 31, 2022, unaudited and subject to change.","NDA for VP-102 (molluscum contagiosum) resubmitted Jan 23, 2023; PDUFA goal date expected H2 2023.","New CMO partner Piramal Pharma Solutions selected; technology transfer completed Jan 2023.","VP-315 Phase 2 Part 1 (10 patients) showed favorable safety, no serious adverse events; Part 2 to start Q2 2023.","Phase 3 trial for VP-102 (external genital warts) expected to initiate H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319503,"accession_number":"0001193125-23-022755","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2023-02-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Verrica posts updated corporate presentation; no material specifics disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company furnished an updated corporate presentation under Regulation FD on Feb 2, 2023.","Presentation posted on Verrica's website; no financial or operational guidance provided in filing.","No material new facts available from the exhibit summary provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319502,"accession_number":"0001193125-23-013704","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2023-01-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Verrica resubmits NDA for VP-102 (molluscum contagiosum) to FDA","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Resubmitted the New Drug Application for VP-102 to the FDA on January 24, 2023.","VP-102 is intended for the treatment of molluscum contagiosum.","No additional details regarding the resubmission content or timeline were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337695,"accession_number":"0001193125-22-279108","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Verrica Q3 net income $83K; reiterates VP-102 NDA resubmission in Q1 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 GAAP net income of $83K ($0.00/sh) vs net loss of $12.8M in Q3 2021; non-GAAP net income $2.9M ($0.07/sh).","License revenue of $8.3M from Torii milestone; cash, equivalents and marketable securities total $39.5M.","Reiterates plan to resubmit NDA for VP-102 (molluscum contagiosum) in Q1 2023.","Phase 2 trial of VP-LTX-315 (basal cell carcinoma) Part 1 expected to conclude in Q1 2023.","R&D and G&A expenses declined vs prior year due to reduced headcount and lower CMC costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":8964000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355079,"accession_number":"0001193125-22-244283","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2022-09-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Verrica posts updated corporate presentation; no material details provided in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing under Item 7.01 Regulation FD discloses updated corporate presentation posted on company website.","Exhibit 99.1 consists only of a cover page; no specific financial or strategic updates are included in the filing.","Presentation may contain operational updates, but content is not summarized in this 8-K.","No changes to guidance, pipeline, or financials are explicitly stated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355078,"accession_number":"0001193125-22-218004","cik":1660334,"company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Verrica Q2 net loss $10.2M; plans VP-102 NDA resubmission in Q1 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2022 net loss $10.2M ($0.37 GAAP EPS); non-GAAP net loss $8.8M ($0.32/share).","License revenue $0.2M from Torii; R&D $4.2M, G&A $5.2M.","Held Type A FDA meeting; began working with Piramal for VP-102 bulk solution.","Raised $28.5M gross in July 2022 public offering at $2.10/share.","Cash, equivalents, marketable securities, restricted cash $54.4M as of June 30, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":645000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":96030000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-11T23:59:59+00:00|355078"}